FY26 Results Announcement
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The company reported a strong balance sheet with significant cash reserves and no debt, while also establishing a commercial pathway for its ROXUS product in the United States. Looking ahead, the company aims to execute its US commercial launch for ROXUS and continue developing its SPONTAN and OROFLOW products.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from LTR Pharma
- SPONTAN Real-World Study Reports 93% Response
- LTR Executes U.S. Commercial Agreement with Strive
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- Response to ASX Aware Letter
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
Later from LTR Pharma
- SPONTAN Phase II Final Results
- First ROXUS Prescriptions Fulfilled in the United States
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma